Project Grant HT94252411053
Award Date
11/1/24
Completion Date
10/31/27
Dollars Obligated
$736K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX, USA
Similar Awards
The federal Project Grant award of $728,043 was granted by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to The University of Texas M.D. Anderson Cancer Center in Houston, TX. The funding will support research to delineate the tumor ecology and genomic progression of lobular breast cancers over a period of 3 years from February 2025 to January 2028. This research aims to transform healthcare for military service members, veterans, and the...
The federal Project Grant award of $718,858.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award was granted to The University of Texas M.D. Anderson Cancer Center on February 15, 2025, with a planned completion date of February 14, 2028. As a leading academic cancer research institution, M.D....
The U.S. Defense Health Agency has awarded a $7,001,734 Project Grant to The University of Texas MD Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The grant, which runs from August 15, 2024 to August 14, 2028, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to drive innovative cancer research and explore new approaches to prevention, diagnosis,...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
This federal Project Grant award of $505,071.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by The University of Texas M.D. Anderson Cancer Center to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award period runs from February 15, 2025 to February 14, 2028. The Military Medical Research and Development program funds diverse biomedical research...
This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
The federal Project Grant award of $5,471,258.00 from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to The University of Texas M.D. Anderson Cancer Center supports research aimed at "Targeting Ganglioside GD2 to Overcome Chemotherapy Resistance in Triple-Negative Breast Cancer". This 4-year grant, awarded on September 1, 2025, will fund advanced biomedical research to transform healthcare for military service members, veterans, and the public by...
The federal Project Grant award of $1,144,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research by the University of Texas MD Anderson Cancer Center to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma (CCRCC). The award period runs from September 1, 2025, through August 31, 2028. MD Anderson, a...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $1,635,000.00 to The University of Texas M.D. Anderson Cancer Center to conduct research on targeting the PCTK1 driver kinase in combination with ferroptosis inducers to combat breast cancer brain metastasis. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical...